KORU Medical Systems (NASDAQ:KRMD) Rating Lowered to Buy at Wall Street Zen

KORU Medical Systems (NASDAQ:KRMD) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other analysts have also recently commented on KRMD. B. Riley Financial upped their target price on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Thursday, January 22nd. Craig Hallum reissued a “buy” rating and set a $7.00 price objective on shares of KORU Medical Systems in a research report on Tuesday, January 13th. Lake Street Capital upped their price objective on KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $6.00 target price on shares of KORU Medical Systems in a report on Friday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.50.

KORU Medical Systems Stock Down 0.7%

KORU Medical Systems stock opened at $4.28 on Friday. KORU Medical Systems has a 52-week low of $1.86 and a 52-week high of $6.61. The company has a market cap of $198.46 million, a P/E ratio of -71.33 and a beta of 0.47. The business has a 50-day simple moving average of $5.10 and a two-hundred day simple moving average of $4.80.

KORU Medical Systems (NASDAQ:KRMD) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. The firm had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $10.90 million. KORU Medical Systems had a negative net margin of 6.41% and a negative return on equity of 15.90%. Research analysts anticipate that KORU Medical Systems will post -0.13 EPS for the current fiscal year.

Institutional Trading of KORU Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Lakewood Asset Management LLC lifted its stake in KORU Medical Systems by 2.8% in the 4th quarter. Lakewood Asset Management LLC now owns 73,945 shares of the company’s stock worth $430,000 after purchasing an additional 2,000 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after purchasing an additional 3,478 shares in the last quarter. White Pine Capital LLC increased its holdings in shares of KORU Medical Systems by 1.6% in the second quarter. White Pine Capital LLC now owns 225,425 shares of the company’s stock worth $807,000 after purchasing an additional 3,526 shares during the last quarter. Barclays PLC increased its holdings in shares of KORU Medical Systems by 8.8% in the fourth quarter. Barclays PLC now owns 67,442 shares of the company’s stock worth $392,000 after purchasing an additional 5,457 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of KORU Medical Systems by 24.8% in the fourth quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock worth $162,000 after buying an additional 5,546 shares in the last quarter. 58.60% of the stock is currently owned by institutional investors.

Key Stories Impacting KORU Medical Systems

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: B. Riley raised its price target to $8.00 and maintained a “buy” rating, implying roughly an 87% upside from the current price — a meaningful vote of confidence from a major dealer. Benzinga
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” rating and set a $6.00 target (≈40% upside), adding further analyst support for upside to the stock. Benzinga
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — clear regulatory progress that should aid European commercialization and recurring revenue potential. Las Vegas Sun
• Positive Sentiment: Q4 2025 results beat EPS expectations (loss of $0.01 vs. -$0.02 est.), reported ~20% revenue growth and positive adjusted EBITDA; management also initiated FY2026 guidance with revenue of $47.5M–$50.0M (roughly in line with consensus ~ $48.8M). These operational improvements support medium-term growth prospects. Business Wire – Q4 & Guidance
• Neutral Sentiment: Analysts and the company provided forward revenue guidance but EPS guidance detail was not clearly disclosed in public summaries; revenue range is encouraging but leaves some near-term visibility questions. Q4 Press Release / Slide Deck
• Negative Sentiment: KORU announced a CEO transition: long-time CEO Linda Tharby will retire June 30 and the board appointed Adam Kalberma as successor. Leadership changes introduce short-term execution risk and can pressure the stock until the market judges the new CEO. Business Wire – CEO Transition
• Negative Sentiment: Despite positives, KRMD still shows a negative net margin and negative ROE; valuation and profitability concerns may keep selling pressure, which likely explains why the stock is trading lower even after upgrades and regulatory wins.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.